2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| Flynn James E | 10% Owner | 1,717,033 | Feb 9, 2021 |
| Deerfield Management Company, L.P. (Series C) | 10% Owner | 1,717,033 | Feb 9, 2021 |
| Deerfield Partners, L.P. | 10% Owner | 1,717,033 | Feb 9, 2021 |
| Deerfield Mgmt L.P. | 10% Owner | 1,717,033 | Feb 9, 2021 |
| LAV Biosciences Fund V, L.P. | 10% Owner | 1,405,583 | Feb 9, 2021 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | Feb 18, 2026 | Burroughs Amy L. | CEO | Sell | 37.5 | -14,583 | -4.68% | ✓ | $571.6K |
| Feb 1, 2026 | Feb 2, 2026 | Turner Heather D | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 1, 2026 | Feb 2, 2026 | Tripuraneni Radhika | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 1, 2026 | Feb 2, 2026 | Azelby Robert | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 1, 2026 | Feb 2, 2026 | Quigley Jill M. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 1, 2026 | Feb 2, 2026 | KINDLER JEFFREY B | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 1, 2026 | Feb 2, 2026 | FELLOWS DAVID A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 14, 2026 | Jan 16, 2026 | Kuriakose Emil | Chief Medical Officer | Neutral | 90.0 | +56,250 | 111.68% | ✗ | - |
| Jan 14, 2026 | Jan 16, 2026 | Gengos Andrew | CFO | Neutral | 90.0 | +68,750 | 208.09% | ✗ | - |
| Jan 14, 2026 | Jan 16, 2026 | Burroughs Amy L. | CEO | Sell | 100.0 | +81,251 | 10.14% | ✓ | $2.5M |
| Jan 2, 2026 | Jan 6, 2026 | Burroughs Amy L. | CEO | Sell | 17.5 | -71,339 | -32.63% | ✗ | $2.7M |
| Jan 2, 2026 | Jan 6, 2026 | Kuriakose Emil | Chief Medical Officer | Sell | 26.3 | -1,155 | -2.24% | ✗ | $44.6K |
| Nov 4, 2025 | Nov 5, 2025 | Quigley Jill M. | Director | Sell | 7.5 | -24,520 | -100.00% | ✓ | $441.4K |
| Oct 1, 2025 | Oct 2, 2025 | Kuriakose Emil | Chief Medical Officer | Sell | 27.5 | -944 | -1.80% | ✗ | $7.4K |
| Jul 1, 2025 | Jul 3, 2025 | Kuriakose Emil | Chief Medical Officer | Sell | 27.5 | -853 | -1.60% | ✗ | $3.6K |
| Jun 27, 2025 | Jun 30, 2025 | Gengos Andrew | CFO | Buy | 91.3 | +10,000 | 66.67% | ✗ | $39.3K |
| Jun 25, 2025 | Jun 25, 2025 | Burroughs Amy L. | CEO | Buy | 95.0 | +23,314 | 98.09% | ✗ | $90.2K |
| Jun 13, 2025 | Jun 16, 2025 | Gengos Andrew | CFO | Buy | 95.0 | +15,000 | 100.00% | ✗ | $57.1K |
| Jun 11, 2025 | Jun 12, 2025 | Tripuraneni Radhika | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 11, 2025 | Jun 12, 2025 | Lu Hongbo | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 11, 2025 | Jun 12, 2025 | KINDLER JEFFREY B | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 11, 2025 | Jun 12, 2025 | Turner Heather D | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 11, 2025 | Jun 12, 2025 | Quigley Jill M. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 11, 2025 | Jun 12, 2025 | FELLOWS DAVID A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2025 | Apr 2, 2025 | Kuriakose Emil | Chief Medical Officer | Sell | 27.5 | -952 | -1.75% | ✗ | $2.4K |
| Feb 24, 2025 | Feb 25, 2025 | Gengos Andrew | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 25, 2025 | Gengos Andrew | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 20, 2025 | Feb 24, 2025 | Azelby Robert | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 24, 2025 | Azelby Robert | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 11, 2025 | Strauss David Eric | Principal Accounting Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 1, 2025 | Feb 3, 2025 | Lu Hongbo | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 1, 2025 | Feb 3, 2025 | Tripuraneni Radhika | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 1, 2025 | Feb 3, 2025 | Quigley Jill M. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 1, 2025 | Feb 3, 2025 | KINDLER JEFFREY B | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 1, 2025 | Feb 3, 2025 | FELLOWS DAVID A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 30, 2024 | Feb 3, 2025 | Jung Melita Sun | Chief Business Officer | Buy | 91.3 | +2,250 | 100.00% | ✗ | $11.5K |
| Jan 30, 2025 | Feb 3, 2025 | Kuriakose Emil | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 30, 2024 | Feb 3, 2025 | Burroughs Amy L. | CEO | Buy | 82.5 | +510 | 2.67% | ✗ | $2.6K |
| Jan 2, 2025 | Jan 6, 2025 | Kuriakose Emil | Chief Medical Officer | Sell | 26.3 | -4,481 | -7.63% | ✗ | $25.6K |
| Jan 2, 2025 | Jan 6, 2025 | Vignola Mark J. | CFO | Sell | 20.0 | -17,188 | -18.69% | ✓ | $99K |
| Jan 2, 2025 | Jan 6, 2025 | Quigley Jill M. | Director | Sell | 10.0 | -15,000 | -100.00% | ✓ | $86.5K |
| Dec 12, 2024 | Dec 16, 2024 | Kuriakose Emil | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 5, 2024 | Dec 9, 2024 | Burroughs Amy L. | CEO | Buy | 95.0 | +15,450 | 423.40% | ✗ | $110.5K |
| Nov 18, 2024 | Nov 19, 2024 | Turner Heather D | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 19, 2024 | Turner Heather D | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Sep 12, 2024 | Sep 17, 2024 | Lu Hongbo | Director | Buy | 100.0 | +476,190 | 100.00% | ✗ | $5M |
| Sep 10, 2024 | Sep 12, 2024 | Vignola Mark J. | CFO | Sell | 28.8 | -10,000 | -9.81% | ✓ | $110K |
| Sep 9, 2024 | Sep 11, 2024 | Quigley Jill M. | Director | Sell | 10.0 | -17,235 | -53.47% | ✓ | $172.4K |
| Aug 1, 2024 | Aug 5, 2024 | Quigley Jill M. | Director | Sell | 10.0 | -15,000 | -50.00% | ✓ | $113.6K |
| Jul 15, 2024 | Jul 17, 2024 | GORDON CARL L | Director | Sell | 37.5 | -56,164 | -0.37% | ✗ | $561.6K |
| Jul 15, 2024 | Jul 17, 2024 | ORBIMED ADVISORS LLC | Director | Sell | 37.5 | -56,164 | -0.37% | ✗ | $561.6K |
| Jul 15, 2024 | Jul 17, 2024 | Quigley Jill M. | Director | Sell | 20.0 | -14,765 | -19.75% | ✓ | $147.7K |
| Jul 1, 2024 | Jul 2, 2024 | Tripuraneni Radhika | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 1, 2024 | Jul 2, 2024 | Taylor Ann Elizabeth | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 1, 2024 | Jul 2, 2024 | Lu Hongbo | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 1, 2024 | Jul 2, 2024 | KINDLER JEFFREY B | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 1, 2024 | Jul 2, 2024 | GORDON CARL L | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 1, 2024 | Jul 2, 2024 | FELLOWS DAVID A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 10, 2024 | Jun 14, 2024 | Tripuraneni Radhika | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 10, 2024 | Jun 14, 2024 | Taylor Ann Elizabeth | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 10, 2024 | Jun 14, 2024 | Lu Hongbo | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 10, 2024 | Jun 14, 2024 | Quigley Jill M. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 10, 2024 | Jun 14, 2024 | GORDON CARL L | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 10, 2024 | Jun 14, 2024 | KINDLER JEFFREY B | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 10, 2024 | Jun 14, 2024 | FELLOWS DAVID A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 31, 2024 | Jun 4, 2024 | Yoon Seokho Bryan | COO | Buy | 86.3 | +4,791 | 5.50% | ✗ | $21.3K |
| May 31, 2024 | Jun 4, 2024 | Vignola Mark J. | CFO | Buy | 86.3 | +4,791 | 5.50% | ✗ | $21.3K |
| May 1, 2024 | May 2, 2024 | Jung Melita Sun | Chief Business Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 2, 2024 | Jung Melita Sun | Chief Business Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Apr 1, 2024 | Apr 3, 2024 | Vivo Opportunity, LLC | 10% Owner | Sell | 27.5 | -420,663 | -6.32% | ✓ | $2.8M |
| Mar 19, 2024 | Kuriakose Emil | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Mar 1, 2024 | Mar 5, 2024 | Burroughs Amy L. | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 15, 2024 | Burroughs Amy L. | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 23, 2024 | Jan 25, 2024 | Quigley Jill M. | Sr. Advisor & Strategy Officer | Neutral | 90.0 | +15,000 | 100.00% | ✗ | - |
| Jan 23, 2024 | Jan 25, 2024 | Yoon Seokho Bryan | COO | Neutral | 90.0 | +68,750 | 373.66% | ✗ | - |
| Jan 23, 2024 | Jan 25, 2024 | Vignola Mark J. | CFO | Neutral | 90.0 | +68,750 | 373.66% | ✗ | - |
| Jan 23, 2024 | Jan 25, 2024 | Quirk Erin | President | Neutral | 90.0 | +75,000 | 100.00% | ✗ | - |
| Nov 30, 2023 | Dec 4, 2023 | Yoon Seokho Bryan | COO | Buy | 82.5 | +743 | 4.21% | ✗ | $2.8K |
| Nov 30, 2023 | Dec 4, 2023 | Vignola Mark J. | CFO | Buy | 82.5 | +743 | 4.21% | ✗ | $2.8K |
| Nov 15, 2023 | Nov 17, 2023 | Quigley Jill M. | Sr. Advisor & Strategy Officer | Neutral | 90.0 | +15,000 | 100.00% | ✗ | - |
| Jun 12, 2023 | Jun 14, 2023 | Taylor Ann Elizabeth | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2023 | Jun 14, 2023 | Tripuraneni Radhika | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2023 | Jun 14, 2023 | Quigley Jill M. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2023 | Jun 14, 2023 | FELLOWS DAVID A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2023 | Jun 14, 2023 | GORDON CARL L | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2023 | Jun 14, 2023 | Lu Hongbo | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2023 | Jun 14, 2023 | KINDLER JEFFREY B | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 31, 2023 | Jun 2, 2023 | Vignola Mark J. | CFO | Buy | 91.3 | +9,997 | 130.53% | ✗ | $14.1K |
| May 31, 2023 | Jun 2, 2023 | Yoon Seokho Bryan | COO | Buy | 91.3 | +9,997 | 130.53% | ✗ | $14.1K |
| May 31, 2023 | Jun 2, 2023 | Sundaram Senthil Vel | CEO | Buy | 90.0 | +2,111 | 27.56% | ✗ | $3K |
| Nov 30, 2022 | Feb 3, 2023 | Yoon Seokho Bryan | COO | Buy | 47.5 | +3 | 0.04% | ✗ | $4.2 |
| Nov 30, 2022 | Feb 3, 2023 | Vignola Mark J. | CFO | Buy | 47.5 | +3 | 0.04% | ✗ | $4.2 |
| Feb 1, 2023 | Feb 3, 2023 | Quirk Erin | President | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 30, 2022 | Feb 3, 2023 | Sundaram Senthil Vel | CEO | Buy | 47.5 | +3 | 0.04% | ✗ | $4.2 |
| Dec 23, 2022 | Dec 28, 2022 | ORBIMED ADVISORS LLC | Director | Buy | 90.0 | +137,931 | 2.91% | ✗ | $1000K |
| Dec 23, 2022 | Dec 28, 2022 | GORDON CARL L | Director | Buy | 90.0 | +137,931 | 2.91% | ✗ | $1000K |
| Dec 23, 2022 | Dec 23, 2022 | Vivo Opportunity, LLC | 10% Owner | Buy | 100.0 | +758,620 | 12.86% | ✗ | $5.5M |
| Dec 23, 2022 | Dec 23, 2022 | Lu Hongbo | Director | Buy | 100.0 | +758,620 | 21.18% | ✗ | $5.5M |
| Nov 23, 2022 | Nov 28, 2022 | LAV Biosciences Fund V, L.P. | 10% Owner | Sell | 16.3 | -1,500,000 | -42.92% | ✗ | $8.3M |
| Sep 7, 2022 | Sep 8, 2022 | Vivo Opportunity, LLC | 10% Owner | Buy | 100.0 | +600,000 | 11.32% | ✗ | $2.2M |